Compare Cytokinetics Inc (CYTK) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs LTC Properties Inc — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while LTC Properties Inc trades at $43.29 (market cap $2.27B). The key difference: Cytokinetics Inc is far larger — about 3.8× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and LTC Properties Inc for 89 Days on average.
| CYTK | LTC | |
|---|---|---|
Market Cap | $8.62B | $2.27B |
Volume | 2,594,626 | 574,171 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $43.50 |
52-Week Low | $54.76 | $33.98 |
Typical Hold Time | 19 Days | 89 Days |
Enterprise Value | $8.72B | $3.01B |
Dividend Yield | — | 5.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
LTC Properties trades at $41.81, down 1.48% over the past day. The stock shows a mixed technical picture with a bullish moving average signal but neutral oscillators. Fundamentally, the company reported strong revenue growth to $262.85 million in 2025 and a net income margin of 38.93%, though earnings have been volatile with a recent miss in Q1 2026. Recent corporate actions include ongoing monthly dividends of $0.19 per share and strategic acquisitions to accelerate growth in seniors housing properties.
The outlook for LTC is cautiously optimistic, supported by demographic tailwinds in senior care and a consensus price target of $49.67 implying 19% upside. Key risks include rising interest rates impacting financing costs and execution challenges in transitioning its portfolio. Analyst sentiment is mixed with 32% buy ratings, highlighting balanced risk-reward near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
